GLP-3 (R)

Description

Concentration

• 10 mg per vial

Physical Form

• White lyophilized powder

Product Features

• Freeze‑dried peptide in a sterile 3 mL vial
• Butyl rubber stopper allows multiple punctures while maintaining a secure seal
• RTF vials are depyrogenated and ETO‑sterilized
• Tamper‑evident aluminum flip‑top for added protection

Research Highlights (bullet format)

• Triple Receptor Agonism: GLP‑3 is designed to activate GLP‑1, GIP, and glucagon receptors simultaneously, combining appetite suppression with higher basal metabolism for a dual‑pathway fat‑loss effect.
• Enhanced Energy Expenditure: GCGR activation mobilizes glycogen and lipids, raising resting metabolic rate and promoting continuous fat oxidation—even during sleep.
• Appetite & Gastric Modulation: Potent GLP‑1R and GIPR activity delays gastric emptying and strengthens satiety signals, reducing overall caloric intake without excessive GI discomfort.
• Albumin‑Binding Backbone: A fatty‑acid acylated design extends circulation time, enabling once‑weekly dosing in research and ensuring sustained receptor engagement.
• Early Weight‑Loss Data: Pre‑clinical and Phase 2 studies report body‑weight reductions of up to ~24 % over 48 weeks, along with smaller waist circumference, lower triglycerides, and improved HbA1c.
• Metabolic & Cardiovascular Potential: Current studies explore benefits for insulin sensitivity, lipid regulation, and cardiac function through combined incretin‑ and glucagon‑mediated pathways.

Synonyms / Registry: LY3437943 · 2381089‑83‑2